ERBB2 and neoplasm: Patients in this trial will undergo treatment with HER2 CAR T cells, with the primary objective of evaluating safety and recommending phase 2 dosing, while secondary objectives include evaluating the tumor and immune microenvironment following treatment, and clinical benefit.